StockNews.AI
FOLD
StockNews.AI
190 days

Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025

1. Amicus Therapeutics will announce 2024 financial results on February 19, 2025. 2. The event will include a conference call and live audio webcast. 3. Archived webcasts and presentation materials will be available post-event. 4. FOLD focuses on developing medicines for rare diseases.

4m saved
Insight
Article

FAQ

Why Neutral?

The financial results announcement typically has mixed influences on stock price; past earnings calls have led to minor fluctuations.

How important is it?

Earnings results can impact investor expectations and market perception, affecting FOLD's stock dynamics.

Why Short Term?

Earnings announcements usually affect stock prices in the short-term, often leading to immediate reactions.

Related Companies

FOLD
February 10, 2025 07:00 ET  | Source: Amicus Therapeutics, Inc. PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call. An archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event. About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn. CONTACT: Investors:Amicus TherapeuticsAndrew FaughnanVice President, Investor Relationsafaughnan@amicusrx.com (609) 662-3809 Media:Amicus TherapeuticsDiana MooreHead of Global Corporate Affairs and Communications dmoore@amicusrx.com (609) 662-5079 FOLD–G

Related News